Alzheimer’s: Blood Test Predicts Symptom Onset Years in Advance

A simple blood test is showing promise in predicting the onset of Alzheimer’s disease symptoms years before they manifest, offering a potential turning point in both research and, eventually, clinical care. Scientists at Washington University School of Medicine in St. Louis have developed a model that can forecast symptom onset with a precision of roughly three to four years, a finding published February 19 in Nature Medicine. This advancement could significantly accelerate clinical trials for preventative treatments and help identify individuals who might benefit most from early intervention strategies.

The Promise of p-tau217

The research centers on a protein called p-tau217, found in plasma – the liquid component of blood. By measuring levels of this biomarker, researchers can estimate when an individual might commence to experience cognitive decline associated with Alzheimer’s. Currently, p-tau217 testing is primarily used to diagnose Alzheimer’s in patients already exhibiting cognitive impairment, and isn’t routinely recommended for those without symptoms outside of research settings. Although, this recent function suggests its predictive potential is substantial. The study builds on earlier research demonstrating that plasma p-tau217 levels closely mirror the accumulation of amyloid and tau proteins in the brain – hallmarks of Alzheimer’s disease, often detectable years before noticeable memory problems arise. Washington University Medicine reports that these findings demonstrate the feasibility of using blood tests – a far cheaper and more accessible alternative to brain imaging or spinal fluid tests – for predictive purposes.

How the Prediction Model Works

The study involved analyzing data from 603 older adults participating in two long-running studies: the WashU Medicine Knight Alzheimer Disease Research Center (Knight ADRC) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), which spans multiple research sites across the U.S. Researchers found that the model could estimate the age of symptom onset within a margin of about three to four years. Interestingly, age played a role in the timing; older adults tended to develop symptoms sooner after elevated p-tau217 levels were detected compared to younger individuals. This suggests that older brains may have a reduced capacity to compensate for the underlying disease process. As lead author Kellen K. Petersen, PhD, explained, amyloid and tau accumulation follows a pattern similar to tree rings – the more “rings,” the older the tree. “It turns out that amyloid and tau too accumulate in a consistent pattern and the age they become positive strongly predicts when someone is going to develop Alzheimer’s symptoms,” Petersen said. “We found this is also true of plasma p-tau217, which reflects both amyloid and tau levels.”

Beyond PrecivityAD2: Reliability Across Platforms

The research team tested their model using different p-tau217 diagnostic tests, including PrecivityAD2, a commercially available test developed by C2N Diagnostics, a startup co-founded by WashU Medicine researchers. They also utilized tests from other companies, including one approved by the U.S. Food and Drug Administration. The model’s consistent performance across these various platforms reinforces its reliability and potential for broader application. Nature highlights the significance of this cross-validation.

The Economic Burden of Alzheimer’s and the Need for Early Detection

The potential impact of this research extends beyond scientific advancement. Alzheimer’s disease currently affects over 7 million Americans, and the Alzheimer’s Association estimates the cost of care will reach nearly $400 billion in 2025. While a cure remains elusive, tools that can anticipate symptom onset could be instrumental in delaying or mitigating the disease’s impact. Early detection allows for proactive planning, lifestyle adjustments, and potential participation in clinical trials evaluating preventative therapies. ScienceDaily reports on the potential for this blood test to forecast Alzheimer’s years before memory loss.

What’s Next: Accelerating Research and Refining Predictions

The researchers have made their model development code publicly available to encourage further investigation and collaboration. They’ve also created a web-based application allowing researchers to explore the clock models in greater detail. The immediate focus is on leveraging these models to streamline clinical trials and identify individuals most likely to benefit from preventative interventions. However, the ultimate goal is to provide individuals with personalized predictions of symptom onset, empowering them and their physicians to develop proactive management plans.

Petersen also notes that other blood biomarkers are linked to cognitive decline in Alzheimer’s, and combining these markers in future studies could further refine predictive accuracy. This research represents a significant step forward, but it’s crucial to remember that it’s still an evolving field. Continued research and validation are essential to translate these promising findings into tangible benefits for those at risk of developing Alzheimer’s disease.